Market Overview:
The global Fc fusion protein for autoimmune disease market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of autoimmune diseases, rising awareness about these diseases, and technological advancements in the field of Fc fusion protein therapy. The global Fc fusion protein for autoimmune disease market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into orencia, enbrel, adalimumab (humira), golimumab (simponi), certolizumab pegol (Cimzia), and ustekinumab (Stelara). On the basis of application, the market is divided into rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and other applications. The regional segments include North America, Latin America, Europe Asia Pacific ,and Middle East & Africa .
Product Definition:
Fc fusion protein is a protein that has been fused to the Fc region of an immunoglobulin molecule. The Fc region is responsible for the binding of antibodies to antigens. The Fc fusion protein can be used to treat autoimmune diseases by blocking the activity of antibodies that are involved in the disease process.
Orencia:
Orencia (Ranibizumab) is a fully human monoclonal antibody that binds to the Fc portion of an immunoglobulin and enhances the immune response by increasing antibody production. It is used for treating autoimmune diseases such as Systemic Lupus Erythematosus (SLE), rheumatoid arthritis, psoriasis, etc. Orencia works by targeting B cells that are involved in causing these diseases.
Enbrel:
Enbrel is a drug that belongs to the category of Fusion Protein Therapeutics. It is used for the treatment of rheumatoid arthritis and psoriasis. The active ingredient in Enbrel is called TNF-inhibitor, which works by decreasing inflammation.
Application Insights:
Rheumatoid arthritis was the prominent application segment in 2017 and accounted for a revenue share of over 40%. The increasing prevalence of rheumatoid arthritis is one of the major factors driving this segment. According to research studies, around 1% to 2% of the population suffers from rheumatoid arthritis at any given time. Moreover, as per the U.S. Centers for Disease Control and Prevention (CDC), around 1 in every 3 adults aged between 18 to 64 have some form of arthritis or chronic joint pain today which is expected to increase up till 2030 due largely to an aging population across the globe.
Regional Analysis:
North America dominated the global market in 2017 owing to favorable reimbursement policies, increasing prevalence of rheumatoid arthritis and psoriatic arthritis, and rising healthcare expenditure. Moreover, the presence of key players such as Pfizer Inc.; Johnson & Johnson Services, Inc.; Merck & Co., Inc. is expected to boost regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period due to factors such as growing economy and improving healthcare infrastructure in emerging countries like China and India are expected drive regional demand for fc fusion protein for autoimmune disease products over next eight years. In addition, increasing prevalence of diabetes is also likely to contribute towards regional market growth during same period (2018-2030).
Growth Factors:
- Increasing prevalence of autoimmune diseases across the globe
- Growing awareness about autoimmune diseases and their treatment options
- Rising demand for better and more effective treatment options for autoimmune diseases
- Technological advancements in the field of Fc fusion protein therapy for autoimmune diseases
- increasing investment by pharmaceutical companies in research and development of new therapies for treating autoimmune diseases
Scope Of The Report
Report Attributes
Report Details
Report Title
Fc Fusion Protein for Autoimmune Disease Market Research Report
By Type
Orencia, Enbrel
By Application
Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Other
By Companies
Bristol-Myers Squibb, Amgen, Pfizer, 3SBIO, Celgen Biopharma, Bristol-Myers Squibb
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global Fc Fusion Protein for Autoimmune Disease Market Report Segments:
The global Fc Fusion Protein for Autoimmune Disease market is segmented on the basis of:
Types
Orencia, Enbrel
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol-Myers Squibb
- Amgen
- Pfizer
- 3SBIO
- Celgen Biopharma
- Bristol-Myers Squibb
Highlights of The Fc Fusion Protein for Autoimmune Disease Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Orencia
- Enbrel
- By Application:
- Rheumatoid Arthritis
- Juvenile Idiopathic Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Fc Fusion Protein for Autoimmune Disease Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Fc fusion proteins are a type of protein that are created when two different proteins are fused together. Fc fusion proteins can be used to treat autoimmune diseases, as they help the body fight against the disease by attacking and destroying the cells that cause the autoimmune condition.
Some of the key players operating in the fc fusion protein for autoimmune disease market are Bristol-Myers Squibb, Amgen, Pfizer, 3SBIO, Celgen Biopharma, Bristol-Myers Squibb.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Fc Fusion Protein for Autoimmune Disease Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Fc Fusion Protein for Autoimmune Disease Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Fc Fusion Protein for Autoimmune Disease Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Fc Fusion Protein for Autoimmune Disease Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Fc Fusion Protein for Autoimmune Disease Market Size & Forecast, 2018-2028
4.5.1 Fc Fusion Protein for Autoimmune Disease Market Size and Y-o-Y Growth
4.5.2 Fc Fusion Protein for Autoimmune Disease Market Absolute $ Opportunity
Chapter 5 Global Fc Fusion Protein for Autoimmune Disease Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Fc Fusion Protein for Autoimmune Disease Market Size Forecast by Type
5.2.1 Orencia
5.2.2 Enbrel
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Fc Fusion Protein for Autoimmune Disease Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Fc Fusion Protein for Autoimmune Disease Market Size Forecast by Applications
6.2.1 Rheumatoid Arthritis
6.2.2 Juvenile Idiopathic Arthritis
6.2.3 Psoriatic Arthritis
6.2.4 Ankylosing Spondylitis
6.2.5 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Fc Fusion Protein for Autoimmune Disease Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Fc Fusion Protein for Autoimmune Disease Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Fc Fusion Protein for Autoimmune Disease Analysis and Forecast
9.1 Introduction
9.2 North America Fc Fusion Protein for Autoimmune Disease Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Fc Fusion Protein for Autoimmune Disease Market Size Forecast by Type
9.6.1 Orencia
9.6.2 Enbrel
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Fc Fusion Protein for Autoimmune Disease Market Size Forecast by Applications
9.10.1 Rheumatoid Arthritis
9.10.2 Juvenile Idiopathic Arthritis
9.10.3 Psoriatic Arthritis
9.10.4 Ankylosing Spondylitis
9.10.5 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Fc Fusion Protein for Autoimmune Disease Analysis and Forecast
10.1 Introduction
10.2 Europe Fc Fusion Protein for Autoimmune Disease Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Fc Fusion Protein for Autoimmune Disease Market Size Forecast by Type
10.6.1 Orencia
10.6.2 Enbrel
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Fc Fusion Protein for Autoimmune Disease Market Size Forecast by Applications
10.10.1 Rheumatoid Arthritis
10.10.2 Juvenile Idiopathic Arthritis
10.10.3 Psoriatic Arthritis
10.10.4 Ankylosing Spondylitis
10.10.5 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Fc Fusion Protein for Autoimmune Disease Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Fc Fusion Protein for Autoimmune Disease Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Fc Fusion Protein for Autoimmune Disease Market Size Forecast by Type
11.6.1 Orencia
11.6.2 Enbrel
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Fc Fusion Protein for Autoimmune Disease Market Size Forecast by Applications
11.10.1 Rheumatoid Arthritis
11.10.2 Juvenile Idiopathic Arthritis
11.10.3 Psoriatic Arthritis
11.10.4 Ankylosing Spondylitis
11.10.5 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Fc Fusion Protein for Autoimmune Disease Analysis and Forecast
12.1 Introduction
12.2 Latin America Fc Fusion Protein for Autoimmune Disease Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Fc Fusion Protein for Autoimmune Disease Market Size Forecast by Type
12.6.1 Orencia
12.6.2 Enbrel
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Fc Fusion Protein for Autoimmune Disease Market Size Forecast by Applications
12.10.1 Rheumatoid Arthritis
12.10.2 Juvenile Idiopathic Arthritis
12.10.3 Psoriatic Arthritis
12.10.4 Ankylosing Spondylitis
12.10.5 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Fc Fusion Protein for Autoimmune Disease Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Fc Fusion Protein for Autoimmune Disease Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Fc Fusion Protein for Autoimmune Disease Market Size Forecast by Type
13.6.1 Orencia
13.6.2 Enbrel
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Fc Fusion Protein for Autoimmune Disease Market Size Forecast by Applications
13.10.1 Rheumatoid Arthritis
13.10.2 Juvenile Idiopathic Arthritis
13.10.3 Psoriatic Arthritis
13.10.4 Ankylosing Spondylitis
13.10.5 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Fc Fusion Protein for Autoimmune Disease Market: Competitive Dashboard
14.2 Global Fc Fusion Protein for Autoimmune Disease Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bristol-Myers Squibb
14.3.2 Amgen
14.3.3 Pfizer
14.3.4 3SBIO
14.3.5 Celgen Biopharma
14.3.6 Bristol-Myers Squibb
